TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on March 5, 2026. Those who purchased TLSI shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by t.